Defective CSR with residual SHM activity is a characteristic feature of AD-AID patients harboring heterozygous AICDA mutations, which affect the last 8–12 amino acid C-terminal nuclear export signal domain encoded by exon 5 [10]. This evidence concerns the gene AICDA and Alzheimer disease.